Literature DB >> 11129080

Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection.

B Lausecker1, B Hess, G Fischer, M Mueller, G Hopfgartner.   

Abstract

An analytical method was developed for the determination of bosentan and its three main metabolites in various matrices and species with focus on robustness. The drug assay involved protein precipitation, followed by liquid-liquid extraction and column switching in combination with narrow bore HPLC-MS-MS. Deuterated analogues of the analytes were used as internal standards. The sample preparation procedure was optimised with respect to minimise the suppression effects from different matrices. The drug and its metabolites could be analysed in plasma, serum, bile, and liver samples from man, dog, and rat with a run cycle time of 10 min. The method used always calibration samples made up in human plasma, whereas quality control samples were prepared in human plasma as well as in the identical matrix as the unknown samples. Calibration graphs for the drug and for the metabolites were linear in the range from 1 or 2 to 2000 or 10,000 ng/ml using a sample volume of 0.25 ml. Mean inter-assay precision and accuracy were 3.0% and 98.4%, respectively. Two additional methods were derived from the main method for the analysis of plasma samples only with focus on reduced manual effort and instrumental run cycle time. The modified methods showed a mean inter-assay precision and accuracy of 5.0% and 99.9% for the method using column-switching, and 3.5% and 98.8% for the method using off-line SPE, respectively. All methods proved to be robust, sensitive, and selective during the analysis of several thousand samples.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129080     DOI: 10.1016/s0378-4347(00)00386-8

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  6 in total

1.  Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.

Authors:  Jasper Dingemanse; Dieter Schaarschmidt; Paul L M van Giersbergen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.

Authors:  Jasper Dingemanse; Paul L M van Giersbergen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

Authors:  Paul L M van Giersbergen; Atef Halabi; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

4.  Determination of bosentan in pharmaceutical preparations by linear sweep, square wave and differential pulse voltammetry methods.

Authors:  Alptug Atila; Bilal Yilmaz
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

5.  Spectroscopic analysis of bosentan in biological samples after a liquid-liquid microextraction.

Authors:  Sanaz Sajedi-Amin; Karim Assadpour-Zeynali; Vahid Panahi-Azar; Abbas Kebriaeezadeh; Maryam Khoubnasabjafari; Khalil Ansarin; Vahid Jouyban-Gharamaleki; Abolghasem Jouyban
Journal:  Bioimpacts       Date:  2015-12-27

6.  Development and Validation of a UHPLC UV Method for the In-Process Control of Bosentan Monohydrate Synthesis.

Authors:  Marta Jatczak; Katarzyna Sidoryk; Magdalena Kossykowska; Wojciech Łuniewski; Joanna Zagrodzka; Elżbieta Lipiec-Abramska
Journal:  Chromatographia       Date:  2016-07-09       Impact factor: 2.044

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.